Enterococci, Enterococcus faecalis, and E. faecium, are the most common Gram-positive cocci in the intestinal tract and have been documented to cause infection of the urinary tract and other sites of humans. [1] [2] [3] [4] [5] Increased antimicrobial resistance in enterococci has become a problem in recent years. 6, 7) Vancomycin is often used as a drug of last resort in treatment of antibiotic-resistant, Gram-positive bacterial infections caused by organisms such as multiresistant enterococci, but the treatment is frequently unsuccessful. 8) Thus, the identification of novel agents effective in inhibiting the growth of these strains has gained renewed urgency. 9) Further, an interest in plants with antimicrobial properties has been revived as a consequence of the current problems associated with the use of antibiotics. 10, 11) Panduratin A, a natural chalcone compound isolated from the rhizomes of fingerroot (Boesenbergia rotunda (L.) MANSF, A.), has been reported to posses antibacterial activity against Prevotella intermedia, P. loescheii, Porphyromonas gingivalis, Propionibacterium acnes, and Streptococcus mutans, as well as antibiofilm activity against multispecies oral biofilms, in vitro. [12] [13] [14] [15] Panduratin A has also been reported to have strong antimicrobial activity against clinical Staphylococcus strains.
antimicrobial agents against E. faecalis strain ATCC 29212 and 23 isolates of clinical enterococci using the method described in the CLSI M7-A6 guidelines. 17) A 2-fold dilution of panduratin A stock solution or other antimicrobial agent preparation was mixed with the test organisms (5ϫ10 5 colony forming unit (CFU)/ml) in Mueller-Hinton broth (MHB) medium (Difco Becton Dickincon, Sparks, MD, U.S.A.). The dilutions were started from the wells in column 12 of the microtiter plate. Thus, column 12 of the microtiter plate contained the highest concentrations of panduratin A or other antimicrobial agents, and column 3 contained the lowest concentrations of panduratin A or other antimicrobials agents. Column 2 served as the positive control for all samples (only medium and inoculum or antimicrobial agent-free wells), and column 1 was the negative control (only medium, no inoculum, no antimicrobial agent). Microtiter plates were incubated aerobically at 37°C for 24 h. The MIC was defined as the lowest concentration of antimicrobial agent that resulted in the complete inhibition of visible growth.
Panduratin A was diluted in 10% DMSO followed by 2-fold dilutions in the test wells; thus, the final concentration of DMSO would be serially decreased. We examined the effect of DMSO on the growth and viability of all clinical enterococci tested. DMSO at Յ10% was found not to affect growth or viability of the enterococci tested. These results suggest that DMSO had no effect on activity and that all measured antimicrobial activity was due to panduratin A. Specific MIC breakpoints (in mg/ml) were as follows (S, susceptible; I, intermediate; and R, resistant): ampicillin, Յ8, -, Ն16; daptomycin, Յ4, -, -; erythromycin, Յ0.5, 1-4, Ն8; levofloxacin, Յ2, 4, Ն8; linezolid, Յ2, 4, Ն8; tetracycline, Յ4, 8, Ն16; and vancomycin, Յ4, 8-16, Ն32.
17)
MBCs were determined for each agent for all clinical enterococci isolates, as described for determination of MICs, by removing the medium from each well that showed no visible growth and subculturing onto MHA (MHB supplemented with 1.5% bacterial agar) plates. Briefly, medium (approximately of 100 ml) from each well showing no visible growth was spread onto MHA plates. Wells in column 2, the positive controls (antimicrobial agent-free wells), and wells in column 1, growth-negative controls, were included in the MBC test. Plates were incubated at 37°C for 24 h or until growth was seen in the growth positive control plates. MBC was defined as the lowest concentration of antimicrobial agent at which all bacteria in the culture are killed or the lowest concentration at which no growth occurs on MHA plates. 18, 19) Time-Kill Assay A time-kill assay was performed on each of all enterococci clinical isolates and E. faecalis reference strain ATCC 29212. Time-kill assays were performed in MBH medium, according to the method of Lorian 18) and Pankey and Ashcraft with modification. 20) Briefly, the adjusted inoculum suspension of 5ϫ10 7 CFU/ml was diluted 1 : 10 in MHB medium to a final concentration of 5ϫ10 6 CFU/ml. Each concentration of panduratin A was diluted 1 : 10 in MHB medium containing 5ϫ10 6 CFU/ml. This yielded an initial inoculum of 4.5ϫ10 6 CFU/ml. Final concentrations of panduratin A were 0ϫ MIC, 0.5ϫ MIC, 1ϫ MIC, 2ϫ MIC, and 4ϫ MIC for each Enterococcus isolate. Cultures (5 ml final volume) were incubated at 37°C with 200 rpm agitation. At pre-determined time points (0, 15, 30, and 45 min as well as 1, 2, and 4 h), 100-ml aliquots were removed and transferred to Eppendorf tubes, centrifuged (3900 rpm at 4°C for 1 min) and rinsed twice with 900 ml of sterile distillated water to obtain panduratin A-free cells. Pellets were suspended in 100 ml of MHB medium and serially diluted. An appropriate volume (100, 50, or 25 ml, depending on the dilution and the concentration of panduratin A) was spread onto MHA plates and incubated at 37°C for 48 h or more, until the colonies appeared on the plates, to determine the number of CFU/ml. Assays were carried out on three different occasions, in triplicate.
In Vitro Biofilm Formation Enterococcal biofilms were allowed to form in the wells of commercially available, presterilized, polystyrene flat-bottomed 96-well microtiter plates, as previously described by Sandoe et al. 21) with modification. Briefly, the wells of microtiter plates were filled with 100 ml of brain heart infusion (BHI) medium. Biofilms were generated by pipetting 100 ml of the standard inoculum (5ϫ10 6 CFU/ml) into selected wells of the microtiter plates, resulting in final inoculums of 2.5ϫ10 6 CFU/ml. The plates were covered and sealed with parafilm. Plates were incubated at 37°C without agitation for 24 h. After incubation, the medium was discarded, and nonadherent cells were removed by thoroughly washing the biofilm three times with sterile phosphate buffered saline (PBS). The plates were inverted and drained by blotting them with paper towels to remove any residual medium. Biofilms were then ready to be assessed for their biofilm-forming capacity and sensitivity to panduratin A and others antibacterial agents.
Quantification of Enterococcal Biofilm Quantification of staphylococci biofilms were carried out using 0.1% crystal violet as previously described. 22, 23) Briefly, washed adherent cells, as described in the section: "in vitro biofilm formation," were stained with 0.1% crystal violet. The crystal violet was solubilized using 30% glacial acetic acid for 15 min. Relative biofilm formation was assayed by reading optical density at 550 nm using a microtiter plate reader (VER-SA MAX , Sunnyvale, CA, U.S.A.).
Sessile Minimal Inhibitory Concentrations (SMICs) and Minimal Biofilm Eradication Concentrations (MBECs) SMICs and MBECs of panduratin A and other antibacterial agents on established staphylococci biofilms were verified in commercially available, presterilized, polystyrene, flat-bottomed 96-well microtiter plates, as described above. Briefly, washed adherent cells were filled with 200 ml 2-fold dilutions of the panduratin A or other antibacterial agents in BHI, ranging from the 1-512 mg/ml. The dilutions were started from the wells in column 12 of the microtiter plate. Thus, column 12 of the microtiter plate contained 512 mg/ml of panduratin A or other antimicrobial agents, and column 3 contained 1 mg/ml of panduratin A or other antimi- crobials agents. Column 2 served as the positive control for all samples (only medium and inoculum or antimicrobial agent-free wells), and column 1 was the negative control (only medium, no inoculum, no antimicrobial agent). The plates were incubated for 24 h at 37°C. The biofilms where then washed and stained, as described above. The optical density (OD 550 ) was measured at time 0 h and after incubation for 24 h. The SMIC was defined as the lowest concentration where no growth occurred in the supernatant fluid, confirmed by no increase in OD 550 compared to the initial reading. SMIC 50 was defined as the lowest concentration of antibacterial agent at which 50% of staphylococci biofilms OD 550 were inhibited. SMIC 90 was defined as the lowest concentration of antibacterial agent at which 90% of staphylococci biofilms OD 550 were inhibited.
MBECs were determined, as follows: washed biofilms from the bottom of treated wells were scarred with a metal loop and spread over the surface of BHA (BHI supplemented with 15% bacterial agar) plates then incubated for 24 h at 37°C. The MBEC was determined to be the lowest concentration at which no bacterial growth occurred on the BHA plates. MBEC 50 was defined as the lowest concentration of antibacterial agent at which 50% of enterococcal biofilms showed no bacterial growth on the BHA plates. MBEC 90 was defined as the lowest concentration of antibacterial agent at which 90% of enterococcal biofilms showed no bacterial growth on the BHA plates. Data from at least four time points of experiment with four replicates each were evaluated and calculated.
RESULTS AND DISCUSSION
The MICs and MBCs of panduratin A against 23 isolates of clinical enterococci are shown with those of ampicillin, daptomycin, erythromycin, eugenol, gentamicin, levofloxacin, linezolid, tetracycline, and vancomycin in Table 1 . Based on the CLSI break points, all clinical enterococci isolates were resistant to ampicillin and erythromycin. 17) Moreover, more than 90% of clinical enterococci isolates were resistant to levofloxacin and vancomycin, and 40% were resistant to tetracycline. All clinical enterococci isolates were susceptible to daptomycin and linezolid. The break point of gentamicin against enterococci is not available in CLSI. 17) Our results show that all isolates were susceptible to panduratin A, with MICs of Յ2 mg/ml and MIC 90 of 1 mg/ml. In our previous report, the MIC of panduratin A against P. gingivalis, P. loescheii, and S. mutans was 4 mg/ml, while that of panduratin A against P. intermedia and P. acnes was 2 mg/ml. [12] [13] [14] Moreover, panduratin A had a MIC 90 of 1 mg/ml for clinical staphylococcal isolates (nϭ108). 16) These results show that panduratin A has stronger activity against clinical enterococci isolates than against P. gingivalis, P. loescheii, and S. mutans, and comparable or equal to that against P. intermedia, P. acnes, and clinical Staphylococcus strains. Panduratin A has been shown to prevent biofilm formation of primary multi-species oral bacteria (Actinomyces viscosus, S. mutans, and S. sanguis) in vitro. 15) The MIC 90 of panduratin A against all clinical enterococci isolates (2 mg/ml) was also much lower than that of ampi- cillin (256 mg/ml), erythromycin (256 mg/ml), gentamicin (512 mg/ml), levofloxacin (32 mg/ml), tetracycline (64 mg/ml), and vancomycin (128 mg/ml), indicating that panduratin A has stronger anti-enterococcal activity against clinical enterococci isolates than any of these commonly used antimicrobial agents. Our results show that the growth of all clinical enterococci isolates was inhibited by Յ2 mg/ml of panduratin A. The activity of panduratin A against all clinical enterococci isolates was comparable or equal to that of daptomycin (Յ4 mg/ml) and linezolid (Յ2 mg/ml).
The in vitro MBCs of panduratin A with an endpoint of 24 h demonstrated that panduratin A was able to kill all clinical enterococci isolates with MBCs of Յ8 mg/ml. Even though, the MICs of daptomycin (Յ4 mg/ml) and linezolid (Յ2 mg/ml) against all clinical enterococci isolates was equal with the MIC of panduratin (Յ2 mg/ml), but the MBCs of daptomycin (Յ16 mg/ml) and linezolid (Յ32 mg/ml) were higher than that of panduratin A (Յ8 mg/ml), indicating that panduratin A has a stronger antimicrobial activity against all clinical enterococci isolates. The MBC of panduratin A against all clinical enterococci isolates was also much lower than that of ampicillin (Յ256 mg/ml), erythromycin (512 mg/ ml), gentamicin (Ͼ512 mg/ml), levofloxacin (Յ256 mg/ml), tetracycline (Յ256 mg/ml), and vancomycin (512 mg/ml). These results suggest that panduratin A has very strong bactericidal activity against all clinical isolates. In addition, the MBC of panduratin A against P. ginggivalis, P. loescheii, and S. mutans was 8 mg/ml, the MBC of panduratin A against P. intermedia and P. acnes was 4 mg/ml, and the MBC of panduratin A against 108 isolates of clinical Staphylococcus was Յ8 mg/ml. [12] [13] [14] [15] In the time-kill assays, panduratin A significantly inhibited bacterial growth compared to control cultures (Fig. 2) . The bactericidal activity of panduratin A was fast-acting against E. faecalis ATCC 29212, E. faecalis clinical isolate #10, and E. faecium clinical isolate #6; the reduction in the CFU/ml was Ͼ3 log units (99.9%) at a panduratin A concentration of 2ϫ MIC. The bactericidal endpoints for E. faecalis ATCC 29212, E. faecalis clinical isolate #10, and E. faecium clinical isolate #6 were reached after 45 min of incubation at a panduratin A concentration of 2ϫ MIC or after 30 min of incubation at a panduratin A concentration of 4ϫ MIC.
Panduratin A was evaluated for antibiofilm activity against 23 isolates of clinical enterococci isolates. The results are summarized in Table 2 and discussed in comparison to daptomycin and linezolid. All clinical enterococcal isolates were susceptible to daptomycin and linezolid. Even though daptomycin and linezolid were effective against the planktonic growth of enterococcal strains, these drugs did not demonstrate strong activity against biofilm-producing enterococcal strains. The SMICs and MBECs of daptomycin and linezolid against biofilm-producing enterococcal strains were Յ16 mg/ml and Յ64 mg/ml, respectively. Interestingly, the growth of biofilm-producing enterococcal strains can be inhibited by panduratin A at concentrations of Յ4 mg/ml. The biofilmproducing enterococcal strains can be eradicated by panduratin A at concentrations of Յ16 mg/ml (Table 1) . These results indicate that panduratin A has stronger activity against biofilm-producing enterococcal strains than daptomycin and linezolid.
In conclusion, panduratin A is an antimicrobial agent with high in vitro activity against clinical isolates, including multidrug-resistant strains. Our results strongly suggest that panduratin A should undergo further testing to assess its potential for the treatment of diseases caused by enterococci. It is important to note that the activities of phytochemicals like panduratin A might be non-specific and affected in the presence of serum. In this research, all tests have been conducted in vitro, thus further studies are necessary to elucidate its antibacterial activities in vivo.
